Frelii Announces Master License Agreement with Systemic Formulations
LEHI, UTAH / ACCESSWIRE / November 12, 2019 / Frelii, Inc. (OTC PINK:FRLI) (“Frelii” or the “Company”), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today it has signed a Master License Agreement (“Agreement) with Systemic Formulations Inc. (“Customer”).
“We believe the efficacy of our genome discovery artificial intelligence, Navii, has been further validated today, as trusted leading nutraceutical company Systemic Formulations has begun selling DNA kits to its network of healthcare practitioners using Navii to provide market leading analysis,” stated Frelii CEO, Ian Jenkins. “As we continue to execute our commercialization strategy we believe the success of the distribution and licensing agreements announced to date will catalyze similar opportunities and position the company for ongoing growth in the 2020″
Under the terms of the Agreement, the Company has granted Customer a non-exclusive license to sell and utilize its artificial intelligence products for an initial term of three years. The Company will charge fees for the use of Navii, and participate in future revenues of Customer products.
About Systemic Formulations Inc.
Systemic Formulations is a leading nutraceutical company utilizing a proprietary blend of vitamins, minerals, enzymes, RNA/DNA tissue factors, amino acids, and botanicals which are synergistically formulated to target particular health issues as well as support general wellness. Tested and proven by users for over fifty years, these products are developed to aid the body’s vital functions such as the immune system, organ function, and overall wellness.
About Frelii Inc.
Frelii Inc. is a biotechnology company utilizing human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome. The resulting data provides valuable insight into an individual’s DNA which are aligned and leveraged against its AI as a means of creating a robust data platform for use by a variety of sectors, including Health & Wellness, Healthcare, Medical Cannabis and Pharmaceutical.
For more information, please visit www.frelii.com or follow us online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/
For questions or inquiries please contact Seth Jones:
Safe Harbor Statement:
This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.
SOURCE: Frelii, Inc.
View source version on accesswire.com: